A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this research is to find out if patients with Type 2 Myocardial Infarction (T2MI) without significant epicardial coronary artery disease (CAD) have a greater chance of having coronary microvascular disease (CMD).
Eligibility criteria
Qualifiers
Ability to give informed consent
Structurally normal heart (normal LV and RV function, no more than mild valvular heart disease)
For controls: atypical chest pain with indication for CMD testing
For T2MI: meet criteria for T2MI according to the 4th Universal definition of MI (rise/fall of troponin with at least 1 value >99th centile+ evidence of symptoms or signs of myocardial ischemia)
Disqualifiers
Acute coronary event (evidence of plaque rupture, fissure or dissection on coronary angiogram)
Known to have angiographically significant CAD/pressure wire positive for epicardial CAD
Inability to receive heparin products
Allergy/contraindication to acetylcholine/adenosine/nitroglycerine products
Trial design
Treatments tested in this trial
- Coronary angiogram with coronary reactivity testing (CRT)
Treatment groups
52 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov